The Clozapine REMS (Risk Evaluation and Mitigation Strategy) is a safety program required by the Food and Drug Administration (FDA) to manage the risk of severe neutropenia associated with clozapine treatment. Severe neutropenia (absolute neutrophil count (ANC) less than 500/µL), can lead to serious and fatal infections..